Background: Genetic background plays a role in multiple myeloma susceptibility. Several single-nucleotide polymorphisms (SNP) associated with genetic susceptibility to multiple myeloma were identified in the last years, but only a few of them were validated in independent studies.
Genetic background plays a role in multiple myeloma susceptibility. Many studies on genetic variants and multiple myeloma risk were published from 2000-2010 (reviewed in refs. 1, 2). Candidate genes were selected for their functional relevance in multiple myeloma and in cancer biology. They belonged to four main categories: cell signaling and growth factors, cytokines, xenobiotic metabolism and transport, and DNA repair and apoptosis. The main limitation of these studies was often a small sample size and lack of statistical power.
Three loci were recently found associated with multiple myeloma in the first genome-wide association study (GWAS; ref. 3) , and were subsequently replicated in the International Multiple Myeloma rESEarch (IMMEnSE) consortium (4) . A more recent extension of the GWAS yielded four more loci (5) .
We attempted to replicate the strongest associations reported for multiple myeloma. Among 43 studies on single-nucleotide polymorphisms (SNP) and multiple myeloma risk (excluding those performed in the context of IMMEnSE and the GWAS), 25 reported at least one significant association at the conventional threshold of P < 0.05. From these, we selected all SNPs reported with P 0.01. The selected variants encompassed all the four groups of genes previously described and included: rs2227667 (SERPINE1), rs17501108 (HGF), rs2195239 (IGF2), rs2373722 (IGF1), rs3136685 (CCR7), rs1800587 (IL1A), rs16944 (IL1B), rs315952 (IL1RN), rs12147254 (TRAF3), rs1805087 (MTR), rs7965399 (IGF1), rs1800629 (TNF-a), rs7516435 (CASP9), rs1042265 (BAX), rs2234922 (mEH), and rs1801133 (MTHFR). We excluded rs2195239 (IGF2), rs2373722 (IGF1), and rs7965399 (IGF1) as in the original study they reached statistical significance only in a secondary analysis but not in the first case-control set (6) . We excluded also rs1800587 (IL1A) and rs315952 (IL1RN), because they were strongly deviating from Hardy-Weinberg equilibrium (HWE) in the controls in the original study (7) . We thus selected 11 SNPs for genotyping: rs2227667 (SERPINE1), rs17501108 (HGF), rs3136685 (CCR7), rs16944 (IL1B), rs12147254 (TRAF3), rs1805087 (MTR), rs1800629 (TNF-a), rs7516435 (CASP9), rs1042265 (BAX), rs2234922 (mEH), and rs1801133 (MTHFR).
Our study population consisted of 1,498 multiple myeloma cases and 1,934 controls recruited from 7 European countries in the context of IMMEnSE (Table 1 ; ref. 5). Cases were defined by a confirmed diagnosis of multiple myeloma according to the International Myeloma Working Group criteria. Region-specific controls were selected among the general population or among hospitalized subjects with diagnoses excluding cancer. For each subject, informed consent was obtained and the study was approved by the relevant ethical committees. Some of the samples had been already genotyped for some of the SNPs in previously published studies and were therefore excluded from genotyping.
We performed the genotyping with TaqMan (Applied Biosystems) and KASPar (KBioscence) technologies. Ten percent of the samples were duplicated for quality control; their genotypes showed greater than 99% concordance. Once subjects with call rate <75% were removed, all SNPs had a call rate over 96%, which was uniform between cases and controls and in all the subpopulations. All the SNPs were in HWE in controls, except rs1800629 (TNF-a) in the Polish subpopulation (P < 0.001), which was therefore excluded from further analyses.
Association between SNPs and multiple myeloma risk was assessed with unconditional logistic regression using codominant and dominant inheritance models, adjusting by age, gender, and region of origin. Additional models (log-additive and recessive) were tested depending on the original findings. Mantel-Haenszel and Breslow-Day statistics were used to test for heterogeneity among the IMMEnSE subpopulations. Because this is a replication study, the conventional threshold of P < 0.05 was considered statistically significant. We had greater than 92% statistical power to replicate all the selected findings at the same level of significance of the original study, and greater than 99% to replicate the results from the studies in which cases were only women, conducting gender-stratified analyses. We performed meta-analyses of this replication with results of previous studies with a fixed-effects model. In case of significant heterogeneity among the original study and the replication set, we used a random-effects model. The significant inheritance model in the original study was used for each meta-analysis.
None of the SNPs showed statistically significant associations with multiple myeloma risk ( Table 2 ). The trend test was significant for rs17501108 (HGF; P ¼ 0.017). A stratified analysis by gender was performed for rs2227667 (SERPINE1), rs17501108 (HGF), rs3136685 (CCR7), rs7516435 (CASP9), rs1042265 (BAX), as the original studies were conducted only in women (8-9) . The G/G homozygotes for rs2227667 (SERPINE1) showed a significantly None of the meta-analyses showed any significant association with multiple myeloma risk (data not shown).
In a large study with high statistical power, we showed that none of the previously reported associations with multiple myeloma risk at 11 SNPs replicates convincingly, possibly with the exception of rs2227667 (SERPINE1) in women. Therefore, it is unlikely that any of the investigated SNPs plays a major role in multiple myeloma etiology.
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